Blog

BILLERICA, MA / ACCESS Newswire / July 30, 2025 / Tecogen Inc. (NYSE American:TGEN) will release Q2 2025 financial results on Tuesday August 12^th after close of market. The earnings press release and supplemental earnings presentation will be available on the Company’s website at www.Tecogen.com in the “Investor Relations” section under “Financial Results.” Members of Tecogen’s senior management will hold a conference call and webcast on Wednesday August 13^th at 9:30 AM Eastern Time to discuss the Company’s financial performance for Q2 2025.

The conference call will be available live via telephone and webcast. To listen to the audio portion, dial 877-407-7186 within the US and Canada or 201-689-8052 from other international locations. Participants should ask to join the Tecogen earnings call. Please begin dialing at least 10 minutes before the scheduled starting time. Alternately, to register for and listen to the webcast, go to Webcast.

The earnings conference call will be recorded and available for playback one hour after the end of the call. To listen to the playback dial (877) 660-6853 within the US and Canada or (201) 612-7415 from other international locations. Use Access ID #: 13752231. The webcast will be archived for 14 days following the call.

About Tecogen

Tecogen designs, manufactures, sells, installs, and maintains high efficiency, ultra-clean, cogeneration products including engine-driven combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational and industrial use. The company provides cost effective, environmentally friendly and reliable products for energy production that nearly eliminate criteria pollutants and significantly reduce a customer’s carbon footprint. In business for over 35 years, Tecogen has shipped more than 3,200 units, supported by an established network of engineering, sales, and service personnel in key markets in North America. For more information, please visit www.tecogen.com or contact us for a free Site Assessment.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and other federal securities laws that involve a number of risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “project,” “target,” “potential,” “will,” “should,” “seek,” “could,” “likely,” “may,” “pro forma,” “anticipate,” “continue,” or other variations thereof (including their use in the negative), or by discussions of strategies, plans or intentions. All statements, other than statements of historical fact included in this press release regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update or revise any forward-looking statements.

In addition to those factors described in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and in our Form 8-K, under “Risk Factors,” among the factors that could cause actual results to differ materially from past and projected future results are the following: fluctuations in demand for our products and services, competing technological developments, issues relating to research and development, the availability of incentives, rebates, and tax benefits relating to our products and services, changes in the regulatory environment relating to our products and services, integration of acquired business operations, and the ability to obtain financing on favorable terms to fund existing operations and anticipated growth.

Tecogen Media & Investor Relations Contact Information:

Abinand Rangesh, CEO
P: 781-466-6487
E: Abinand.Rangesh@tecogen.com

SOURCE: Tecogen, Inc.

View the original press release on ACCESS Newswire

Offering Legal Support for Victims of Livestock Accidents Across the U.S.

TURLOCK, CA / ACCESS Newswire / July 30, 2025 / Silva Injury Law, a trusted personal injury firm based in the Central Valley of California, has launched a new national legal resource, LivestockAccidentLaw.com, to help individuals involved in serious motor vehicle accidents caused by livestock on roadways. The website is designed to educate the public about their rights and provide access to legal information and support in the wake of livestock-related collisions.

The site offers detailed guidance on five specific types of accidents involving loose or escaped animals, including:

• Cow Accidents,

• Escaped Livestock Accidents,

• Goat, Sheep, and Other Animal Accidents,

• Horse Accidents, and

• Livestock-Related Wrongful Death.

LivestockAccidentLaw.com provides state-specific resources and answers to common questions about who may be liable for damages after an accident, what steps victims can take immediately afterward, and how claims involving livestock are typically handled in civil court.

The site is intended for use by injured motorists, their families, and attorneys seeking background information on livestock accident liability or representation in a livestock accident claim. Visitors can also find information on wrongful death claims arising from these incidents.

For more details or to learn more about potential legal options following a livestock-related accident, visit https://livestockaccidentlaw.com.

About Silva Injury Law:

Silva Injury Law is a California-based personal injury firm that advocates for individuals harmed due to the negligence of others. The firm handles a broad range of cases, including motor vehicle accidents, wrongful death claims, dog bite injuries, livestock accidents, and other serious personal injury matters. Founded by attorney Michael Joe Silva, a native of California’s Central Valley and graduate of BYU’s J. Reuben Clark Law School, Silva Injury Law is dedicated to providing clients with clear communication, personalized legal support, and committed representation throughout the recovery process.

Contact Information:

Silva Injury Law, Inc.
2857 Geer Rd., Suite B
Turlock, CA 95382
Phone: (209) 600-4389
ilvainjurylawsandiego@lawyermarketingexperts.com

SOURCE: Silva Injury Law, Inc.

View the original press release on ACCESS Newswire

Top Four Conveyor Car Wash Company Opens Fourteenth Location in Virginia

THOMASTON, GEORGIA / ACCESS Newswire / July 30, 2025 / Tidal Wave Auto Spa, one of the nation’s fastest-growing express car wash companies, is pleased to announce its continued expansion in Virginia with the grand opening of the company’s newest location in Danville, VA, at 107 Executive CT.

To celebrate the grand opening, Tidal Wave’s Danville location will offer eight days of free premium car washes from July 30 to August 6. This limited-time promotion provides an opportunity for car owners to experience Tidal Wave’s premium wash option, Graph-X4, at no cost. Additionally, any new customer who joins a Tidal Wave Clean Club unlimited wash membership during Grand Opening week will enjoy their first month of unlimited washes for only $9.97 – saving up to $40.

“We’re thrilled to continue our growth in Virginia with the opening of our new Danville location,” said Scott Blackstock, CEO and Founder of Tidal Wave Auto Spa. “At Tidal Wave, we’re passionate about delivering a top-tier car wash experience that goes beyond just a clean vehicle-it’s about outstanding service, convenience, and consistency. Our team looks forward to sharing our exceptional car wash experience with Danville and the surrounding communities during opening week and beyond.”

Danville, VA Location: 107 Executive Ct, Danville, VA 24541

Nearby Locations: Greensboro, NC,High Point, NC

Tidal Wave Auto Spa proudly serves customers at 297 express wash locations across the United States, including 14 Virginia locations. Tidal Wave is committed to providing every customer with an exceptional car wash experience through industry-leading car care technology, clean and attractive locations, and friendly customer service at every location. With single wash options starting at $12, unlimited car wash memberships and family plans, plus fleet plans for businesses, Tidal Wave has your unique car wash needs covered.

For additional information, including upcoming openings, fundraising, fleet plans, and more, please visit: https://www.tidalwaveautospa.com/.

About Tidal Wave Auto Spa

Tidal Wave Auto Spa was founded over 20 years ago in Thomaston, GA, by husband and wife, Scott and Hope Blackstock. What started as a small-town self-service car wash business evolved into the first conveyor car wash open in Georgia and is now the fourth-largest conveyor car wash company in the nation, with 297 locations spanning 30 states. Tidal Wave is committed to providing every customer an exceptional car wash experience through industry-leading car care technology, clean and attractive locations, and outstanding customer service. Tidal Wave is committed to making a positive impact in the communities it serves, raising over $7 million for local programs, service organizations, and non-profit organizations through the company’s fundraising program and annual philanthropic Charity Day event.

SOURCE: Tidal Wave Auto Spa

Related Images

View the original press release on ACCESS Newswire

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center

FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the “Company”), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd. (“PeriNess”), has entered into a Clinical Study Agreement (the “Agreement”) to support an exploratory clinical study of DNase I in combination with anti-CD19 CAR T cells in patients with large B cell lymphoma.

Dr. Ron Ram, Professor of Medicine and Head of the Bone Marrow Transplantation Unit at the Tel Aviv Sourasky Medical Center (“Sourasky Center”), will act as the principal investigator of the study.

The primary objective of this study is to explore the safety and tolerability of DNase I in combination with anti-CD19 CAR T therapy in subjects with stable or progressive large B-cell lymphoma when DNase I is given in an adjuvant setting. Secondary objectives include efficacy to be evaluated by the measure of complete response rate post CAR T infusion, duration of response and overall survival. The study has the potential for a strong translational component with a complex assessment of biomarker response and analysis of anti-CD19 CAR T expansion and persistence.

“Our data suggests that the degradation of Neutrophil Extracellular Traps (NETs) by DNase I plays a crucial role in maintaining CAR T-cell function and preventing premature CAR T-cell exhaustion. Our preclinical studies conducted show that co-administration of DNase I with anti-CD19 CAR T cells significantly reduce tumor burden, delay tumor relapse and substantially prolong survival compared to the anti-CD19 CAR T cell monotherapy groups in various syngeneic and xenogeneic experimental models of lymphoma and leukemia,” stated Alexey Stepanov, PhD, Institute Investigator at the Scripps Research Institute, and a member of Xenetic’s Scientific Steering Committee.

“Progression of large B cell lymphoma (LBCL) is the major obstacle for the success of CAR T therapies, with approximately 40-60% of the patients relapsing in the first year, and 25-35% within 3 months after CAR T infusion, depending on the CAR T product used. While patients with partial or complete response before CAR T infusion have a 1-year progression free survival of 60-80%, those with stable or progressive disease at the time of CAR T infusion have a 1-year progression free survival of 20-30%. NETs facilitate several hallmarks of cancer biology at various stages, including progression, invasion, metastasis, immunosuppression, immune escape, and resistance to therapy. A high content of NETs in lymphoma tissue and blood of patients was associated with a negative outcome. The goal of this clinical study is to improve clinical response by administering DNase I to abrogate the negative effects of NETs on the performance of immune system and CAR T cells,” added Dr. Ram.

James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic concluded, “We are pleased with the continued progress of our DNase I program and the expansion of its development in another exploratory study to further evaluate its potential in various oncology indications. We look forward to garnering additional data to realize the full potential of DNase I.”

As previously announced, in December 2024, Xenetic entered into a Clinical Trial Services Agreement with PeriNess, under which PeriNess will lead in the regulatory approval, operational execution and management of potential exploratory, investigator-initiated studies of recombinant DNase I as an adjunctive treatment in patients with pancreatic carcinoma and other locally advanced or metastatic solid tumors receiving chemotherapy and immunotherapy in Israeli medical centers.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company’s DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase I program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company’s website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” “remain,” “focus”, “confidence in”, “potential”, and other words of similar meaning, including, but not limited to, all statements regarding expectations with respect to the Clinical Trial Services Agreement with PeriNess, including statements regarding the proposed investigator-initiated study under such agreement to support an exploratory clinical study of our systemic DNase I candidate in patients with large B-cell lymphoma and the expected objectives and goal of such study, and all statements regarding expectations for our DNase-base oncology platform, including statements regarding: our overall development strategy, the progress of our DNase I program, our expectations regarding further expansion of our body of clinical data, our focus on advancing innovative immune-oncology technologies addressing difficult to treat cancers, the DNase technology improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many cancers, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) the relevance of, or our ability to utilize, the data, if any, from any investigator-initiated exploratory study, (2) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements, including the Clinical Trial Services Agreement with PeriNess; (3) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (4) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (5) failure to realize the anticipated potential of the DNase technologies; (6) the ability of the Company to obtain funding and implement its business strategy; and (7) other risk factors as detailed from time to time in the Company’s reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues and geopolitical events, such as the conflicts in the Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

NEW YORK CITY, NY / ACCESS Newswire / July 30, 2025 / While AI tools and platforms are evolving faster than accounting professionals can adapt to them, it is still the people and processes within an organization that make them work. However, when individuals move on, this loss can create gaps within the organization, cracks leading to challenges in maintaining efficiency and continuity. To that end, alexion.ai today comes to market with an all-star executive team to guide the company towards its goal of keeping accounting decentralized, intelligent, and resilient.

Alexion acts as connective tissue across firm systems: normalizing unstructured data, reconciling fragmented context, and building AI-powered memory infrastructure. This foundation enables firm-specific agents to operate with trust, traceability, and nuance.

Alexion is not replacing accountants, they’re amplifying them. Preserving their logic. Codifying their judgment. And transforming individual expertise into shared intelligence that strengthens the entire firm.

In order to guide Alexion.ai’s path and ensure it delivers on all of the promises it makes and the technology it is building, the company has assembled an elite and diverse team of leaders that combine accounting, enterprise SaaS, design, and top-level AI backgrounds.

At the helm as alexion.ai’s CEO and Co-Founder is Lisa Griffith, who spent the last several years taking Laurel.AI to market and growing it to new heights as its head of accounting, go-to-market strategy, and partnerships. But her move to Alexion wasn’t about a product, it was about a pattern.

“I didn’t start with a product idea. I started with a pattern. After years inside firms, listening to partners, operators, and rising talent, I saw what was really eroding: not just efficiency, but continuity. The kind of deep, institutional judgment that lives in people, not platforms. And when those people leave, so does the logic.

Alexion is my response to that pattern. We’re not just building tools-we’re building memory. Infrastructure that captures how firms think, not just what they do. That codifies expertise into reusable logic. That enables AI agents to act with the same nuance and judgment as the professionals they support.

Because firms don’t lose value when someone leaves. They lose value when the way that person reasoned walks out the door with them.”
– Lisa Griffith, CEO & Co-Founder, alexion.ai

For Guthrie Chen, Founder and Chief Visionary Officer of alexion.ai, the journey began with a simple idea: true financial understanding could break down nearly any barrier. His exploration brought him into collaboration with diverse experts, from mathematicians to entrepreneurs, where he saw how their specialized knowledge could be synthesized and automated to build a more accessible financial future for everyone.

“Our focus is on human creativity. AI has already come so far, and we want to build the brain, the ‘accountant’s brain,’ in a way that will evolve the world of accounting and tap into the data at our firms and build data you can trust,” said Chen. “We are making numbers real, as well as understanding each other’s languages and disciplines. You have to have that to build a proper product. Accounting can be very subjective; you have to make sure you aren’t forcing software on someone. As we build our brand and tech, it has to feel adaptive.”

Providing a crucial strategic and operational counterpart to Guthrie and Lisa’s vision is Matt McDonagh, Head of Strategy at Alexion. McDonagh brings a unique perspective forged on Wall Street as an investment banker before he pivoted to technology as an investor and a self-taught data engineer. He applies his expertise in using AI to refine strategy and build the operational backbone for Alexion’s growth.

The core challenge Alexion.ai addresses is data fragmentation. In most firms, institutional wisdom is locked in disconnected silos: scattered across white papers, trapped in internal memos, and separated by disparate accounting systems. This foundational problem became McDonagh’s focus after a pivotal meeting with Guthrie at a Family Office and Blockchain conference in Florida.

Impressed by Guthrie’s accounting background and technological approach, McDonagh was struck by its design philosophy: it was built by an accountant, for accountants. “That perspective was crucial,” McDonagh stated. “It was a tool born from the field. It made me realize the broader opportunity is unifying all of a firm’s existing, fragmented data. We saw AI agents fail because their data is unreliable. We saw an opportunity to transform the industry by aggregating this siloed intelligence. Our goal is to normalize it, creating a single source of truth that empowers everything else.”

Alexion.ai’s leadership team is rounded out by Head of Design Kris Andrews, Head of Product Minza Zahid, and Head of Finance Brian Sholley. Silicon Valley legends in Machine Learning and software engineering are working with the Alexion team to develop the technical roadmap to bring the power of AI to accounting. The company is also supported by an All-Star Advisory Board, including Gary L. Boomer, Rafael Casas, and Dr. Sean Stein Smith.

For more information, please reach out to Lisa Griffith.

Lisa Griffith
CEO
lisa@alexion.ai
5107100587

SOURCE: alexion.ai

View the original press release on ACCESS Newswire

• First sublingual pre-workout single-serving supplement that delivers 50mg of caffeine rapidly to the body, is now available to order via Aspire’s new direct-to-consumer shopping experience

ESTERO, FL / ACCESS Newswire / July 31, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced the rollout of its new e-commerce solution, buzzbomb.buzz with BUZZ BOMB™ as its featured launch product. This new seamless direct-to-consumer shopping experience allows consumers to order BUZZ BOMB™ on the Aspire platform and have them shipped directly to their door with access to exclusive promotions, and customer support. To celebrate the launch, customers who register for Aspire’s e-commerce site will have first access to special pricing, free shipping offers, and other promotions. The site features an introductory sample pack of four flavors as well as 30-packs in various configurations.

“We are excited to launch our new BUZZ BOMB™ e-commerce website in the U.S., which marks a significant step forward for the brand and will provide consumers with a seamless and personalized shopping experience,” said Kraig Higginson, Interim Chief Executive Officer of Aspire. “This launch enables us to offer our advanced sublingual pre-workout supplement-designed to help athletes and fitness enthusiasts maximize their performance potential -directly to customers across the nation and at a competitive price. Together with our significant presence and marketing plans at two of the largest fitness conventions in early August, we are confident that the launch of our e-commerce site will further accelerate the brand’s growth among active and fitness-minded consumers, helping us achieve our goal of providing one of the most advanced caffeine delivery formulas on the market.”

Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout market to help athletes and fitness enthusiasts maximize their performance potential. BUZZ BOMB™, offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue-without any mixing with water or hassle–for immediate effect.

About the Aspire Targeted Oral Delivery Platform

Aspire’s technology delivers fast-acting supplement formulations which have been developed by using our patent-pending methodology, and “trade secret” process. The technology’s new mechanism of action allows for rapid sublingual absorption. The benefits of “rapid absorption” are to provide rapid impact in more precise quantities.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a disruptive technology that can deliver supplements and drugs rapidly and precisely. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire